<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541603</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-LVO-04</org_study_id>
    <nct_id>NCT03541603</nct_id>
  </id_info>
  <brief_title>Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF</brief_title>
  <acronym>HELP</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tenax Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tenax Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with
      placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levosimendan and its prolonged active metabolite, OR-1896, have been shown to have favorable
      hemodynamic effects in subjects with pulmonary hypertension and right heart failure. Clinical
      studies that have been conducted in subjects with right heart failure and pulmonary
      hypertension suggest levosimendan may be an effective therapy in treatment of subjects with
      PH-HFpEF. This study will provide demonstration of levosimendan/OR-1896's effectiveness in
      critical measures of hemodynamic response in weekly administration of levosimendan and the
      concomitant response as measured by exercise capacity, subject quality of life, and changes
      in functional capacity. These data will support and guide the Phase 3 development of
      levosimendan in PH-HFpEF subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">April 7, 2020</completion_date>
  <primary_completion_date type="Actual">April 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Index (CI) at rest and with exercise</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Vascular Resistance (PVR) effect at rest and with exercise</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PCWP when supine and legs elevated</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>Week 6</time_frame>
    <description>Patient assessment of well-being based on 6 questions assessed on a 5-point Likert Scale ( 1 =worst, 5= best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise duration via 6 minute walk test</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's assessment of functional class</measure>
    <time_frame>Week 6</time_frame>
    <description>Physician's Assessment of New York Heart Association (NYHA) Classification (one of four categories based on how much the patient is limited during physical activity. (Class I, no limitation of physical activity to Class IV, marked limitation of physical activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite incidence of death or hospitalization</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hypertension Pulmonary Secondary</condition>
  <condition>Heart Failure, Right Sided</condition>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Levosimendan 2.5mg/mL Injectable Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.075 - 0.1µg/kg/min for 24 hrs (weekly)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.075 - 0.1µg/kg/min for 24 hrs (weekly)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion</description>
    <arm_group_label>Levosimendan 2.5mg/mL Injectable Solution</arm_group_label>
    <other_name>Levosimendan 2.5 mg/mL Injectable Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion</description>
    <arm_group_label>Matching Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Criteria to enter Open-label, Lead-in Dose Phase:

          -  Diagnosis of WHO Group 2 Pulmonary Hypertension (PH) with heart failure and preserved
             ejection fraction (HFpEF) confirmed at the time of the diagnosis of pulmonary
             hypertension.

          -  Baseline Pulmonary Arterial Pressure (PAP) ≥35, PCWP ≥20, NYHA Class IIb/III, Left
             Ventricular Ejection Fraction (LVEF) ≥40%

          -  Ability to walk at least 50 meters, but not more than 550 meters in a six-minute walk
             test.

          -  Stable oxygen treatment (if applicable), and medications for heart failure,
             hypertension and respiratory condition

        Criterion for Randomization to Double-blind Phase:

          -  Response to Open-label, Lead-in Levosimendan: Patients who demonstrate a ≥4mmHg
             reduction in PCWP from baseline measured at bicycle exercise (25 watts) with no more
             than a 10% decrease from baseline in cardiac index

        Exclusion Criteria:

          -  Subject has primary diagnosis of PH other than Group 2 PH-HFpEF

          -  Previous Percutaneous Coronary Intervention (PCI) or cardiac surgery (CABG) , unless
             they have a negative stress test in last 12 months)

          -  Congenital heart disease

          -  Clinically significant lung disease

          -  Planned heart or lung surgery

          -  Cardiac Index &gt;4.0 L/min/m2

          -  Concomitant administration of pulmonary vasodilator therapy or taken within 14 days

          -  Dialysis or Glomerular Filtration Rate (GFR) &lt;30 mL/min/1.73 m2

          -  Liver dysfunction with Child Pugh Class B or C

          -  Evidence of systemic infection

          -  Weight &gt; 150kg

          -  Symptomatic systolic blood pressure (SBP) cannot be managed to ensure SBP &gt;100 mmHg

          -  Heart rate &gt;= 100 bpm with study drug, symptomatic and persistent for at least 10
             minutes

          -  Hemoglobin &lt; 80 g/L

          -  Serum potassium &lt; 3.0 mmol/L or &gt; 5.5 mmol/L at baseline

          -  Patients having severely compromised immune function

          -  Pregnant, suspected to be pregnant, or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Healthcare</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichan School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Health University Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PH-HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

